KalVista Pharmaceuticals, Inc. (KALV) Analysts See $-0.45 EPS on March, 15

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)’s earnings release is anticipated by WallStreet on March, 15, Faxor reports. Analysts predict $-0.45 EPS, which is $0.04 up or 8.16 % from 2018’s $-0.49 EPS. 104.55 % negative EPS growth is what analysts predict. $-0.22 EPS was published for previous quarter. KALV is reaching $26.23 during the last trading session, after increased 9.84%.KalVista Pharmaceuticals, Inc. is uptrending after having risen 120.29% since March 14, 2018. KALV has 325,021 volume or 356.13% up from normal. KALV outperformed by 115.92% the S&P 500.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors.The firm is valued at $451.83 million. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.Last it reported negative earnings. The Company’s products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE.

For more KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) news released recently go to: Seekingalpha.com, Seekingalpha.com, Businesswire.com, Businesswire.com or Businesswire.com. The titles are as follows: “The Vision Is Clear: Listen To Merck And Invest In Microcap KalVista Pharmaceuticals – Seeking Alpha” released on October 18, 2017, “Merck Has Strong Conviction In KalVista’s Phase 2 Clinical Trial Of KVD001 In DME – Seeking Alpha” on January 22, 2018, “KalVista Pharmaceuticals Commences Two Clinical Trials – Business Wire” with a publish date: January 05, 2018, “KalVista Pharmaceuticals Reports Fiscal First Quarter Results – Business Wire” and the last “KalVista Pharmaceuticals Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Over-allotment Option to Purchase Additional Shares – Business Wire” with publication date: September 10, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.